Established in 2003 by Prof. Raymond Kaempfer and Dr. Gila Arad from the faculty of medicine at the Hebrew University, Atox Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients.
Reltecimod, Atox Bio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life threatening infection for which no therapy currently exists.
Atox Bio recently completed ACCUTE (Reltecimod Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions), a phase 3 clinical trial evaluating the efficacy of Reltecimod in patients with NSTI. Previously, the company completed a phase 2 study of Reltecimod in NSTI. Results demonstrated that patients treated with Reltecimod had a meaningful improvement across multiple end points.
Reltecimod is also being studied in REAKT (Reltecimod Efficacy for Acute Kidney Injury Trial), a phase 3 study in patients with abdominal sepsis induced Acute Kidney Injury (SA-AKI).Reltecimod was granted Fast Track status and Orphan Drug designation from the FDA as well as Orphan Medicinal Product designation from the European Commission.
Reltecimod development is supported by a contract from BARDA (Biomedical Advanced Research and Development Authority).